ReviewBlood reviews2026
Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.
Review in Blood reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acute myeloid leukemia (AML) is a complex, heterogeneous and aggressive hematopoietic clonal disorder with limited curative options beyond allogeneic stem cell transplantation. The disease presents significant challenges due to high relapse rates resistance to chemotherapy, and the immunosuppressive tumor microenvironment. The immune system plays an important role in leukemia survival and resistance. Various immunotherapeutic approaches, ranging from the use of monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTE's), chimeric antigen receptor T (CAR-T) cells, vaccines and therapeutic infusions of NK cells, are currently being tested with promising, yet conflicting results. We review the various types of immunotherapies in pre-clinical and clinical development and discuss how best to use them in clinical practice from the point of view of a clinical hematologist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.